Patented biomaterial in catheters used to reduce thrombus accumulation1

BEDFORD, MA--(BUSINESS WIRE)--Access Vascular, Inc. today announced that the FDA has approved its HydroMID™ midline catheter. HydroMID is made of Access Vascular’s ​​proprietary biological material, which has been proven to reduce thrombus accumulation by up to 97% compared to standard polyurethane catheters. 1 is the second device in its planned portfolio to be cleared.

Due to its inclusion in the MAGIC (Michigan Appropriate Guidelines for Intravenous Catheters) guidelines, midline catheters are gaining popularity and eliminate the need for confirmatory chest X-rays for midline placement. The standard centerline is composed of polyurethane or silicone, which may cause protein adsorption. 2 This may cause blood clots to accumulate 3 or catheter-related infections. 4

HydroMID is a 4 French, single lumen, midline catheter with a maximum usable length of 20 cm. HydroMID will be launched in the next few weeks to obtain clinical feedback on the use of this midline catheter.

The company’s expansion to the midline allows healthcare professionals to choose between midline or peripheral insertion of the central catheter made of this new anti-thrombotic biomaterial according to their needs. Compared with peripheral intravenous catheters (IV), due to fewer restarts, the midline can be used for up to 30 days, so the patient's comfort is usually higher. 5

The midline release also further advances the company's plan to develop a combination of anti-thrombotic venous catheters and equipment composed of its proprietary biomaterials to address the US$4.4 billion venous access market. The company's first product, HydroPICC™, was approved by the FDA last year and is currently being commercially promoted in the United States, focusing on obtaining real-world clinical data.

James Biggins, Chief Executive Officer of Access Vascular, said: "The FDA's approval of our second device demonstrates our commitment to providing a complete portfolio of venous access solutions and our commitment to help clinicians solve the complications of thrombosis and catheter occlusion that plague patients. "I am proud that our entire team is licensed. We look forward to working with clinicians to integrate our equipment into their workflow and to better understand the benefits we can bring to patient treatment and care. "

Access Vascular was established in 2015 to solve the most common and expensive complications of intravenous therapy: infection, thrombosis and phlebitis. The company is developing a set of venous access devices made of patented biomaterials that are highly biocompatible and able to resist thrombosis for a long time.

Michelle McAdam, Chronic Communications Company michelle@chronic-comm.com (310) 902-1274

Access Vascular announced that its HydroMID midline catheter has received FDA approval, which is made of its proprietary biological material to reduce thrombus accumulation.

Michelle McAdam, Chronic Communications Company michelle@chronic-comm.com (310) 902-1274